SAROJA — Saroja Pharma Industries India Income Statement
0.000.00%
- IN₹171.67m
- IN₹273.56m
- IN₹501.93m
- 16
- 67
- 20
- 23
Annual income statement for Saroja Pharma Industries India, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | PROSPECTUS | PROSPECTUS | PROSPECTUS |
Standards: | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 171 | 367 | 556 | 502 |
Cost of Revenue | ||||
Gross Profit | 17 | 33.2 | 53.1 | 49 |
Selling / General / Administrative Expenses | ||||
Depreciation and Amortization | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 160 | 342 | 515 | 467 |
Operating Profit | 10.9 | 24.4 | 41.2 | 34.6 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | 2.15 | 10.4 | 15.8 | 14.9 |
Provision for Income Taxes | ||||
Net Income After Taxes | 1.61 | 7.31 | 11.4 | 10.6 |
Net Income Before Extraordinary Items | ||||
Net Income | 1.61 | 7.31 | 11.4 | 10.6 |
Adjustments to Net Income | ||||
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | 1.61 | 7.31 | 11.4 | 10.6 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | 0.4 | 1.82 | 2.84 | 2.64 |
Dividends per Share |